GSK (LON:GSK) Given “Underweight” Rating at JPMorgan Chase & Co.

JPMorgan Chase & Co. reiterated their underweight rating on shares of GSK (LON:GSK) in a research report sent to investors on Friday morning, Marketbeat.com reports.

Separately, Berenberg Bank reduced their price objective on shares of GSK from GBX 1,820 ($23.53) to GBX 1,600 ($20.69) and set a “buy” rating for the company in a research note on Friday, November 29th. One analyst has rated the stock with a sell rating, one has given a hold rating and five have given a buy rating to the company’s stock. According to data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus price target of GBX 1,805.83 ($23.35).

GSK Stock Up 0.6 %

GSK opened at GBX 1,486.08 ($19.21) on Friday. The company has a market capitalization of £60.30 billion, a PE ratio of 24.01, a price-to-earnings-growth ratio of 1.24 and a beta of 0.31. The business has a 50-day moving average of GBX 1,456.03 and a 200-day moving average of GBX 1,431.41. GSK has a fifty-two week low of GBX 1,282.50 ($16.58) and a fifty-two week high of GBX 1,823.50 ($23.58). The company has a debt-to-equity ratio of 114.64, a current ratio of 0.81 and a quick ratio of 0.73.

GSK (LON:GSK) last issued its quarterly earnings data on Wednesday, February 5th. The company reported GBX 23.20 ($0.30) earnings per share for the quarter. GSK had a net margin of 8.02% and a return on equity of 18.08%. Equities research analysts forecast that GSK will post 175.980975 EPS for the current fiscal year.

Insider Activity

In other news, insider Emma Walmsley sold 38,459 shares of the company’s stock in a transaction that occurred on Monday, February 17th. The stock was sold at an average price of GBX 1,418 ($18.33), for a total transaction of £545,348.62 ($705,131.39). Also, insider Wendy Becker acquired 536 shares of GSK stock in a transaction dated Thursday, March 20th. The stock was acquired at an average cost of GBX 1,515 ($19.59) per share, with a total value of £8,120.40 ($10,499.61). Insiders own 1.61% of the company’s stock.

GSK Company Profile

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D.